The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Kaleen N Hayes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services, Policy, & Practice, Brown University School of Public Health, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Deprescriptions, Observational Studies as Topic, Pharmacoepidemiology, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Society for Pharmacoepidemiology, NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Purpose
Pharmacoepidemiologic studies on deprescribing are challenging to implement, yet little guidance exists on methods to avoid bias and minimum reporting for replicability and appraisal. We developed consensus recommendations for the methods and reporting of observational studies that aim to examine the effects of deprescribing.
Methods
We formed candidate recommendations based on our prior systematic review that methodologically appraised observational studies on deprescribing. We then conducted a two‐round modified Delphi process with researchers working in deprescribing pharmacoepidemiology to refine, select, and reach consensus on recommendations for a checklist based on > 70% agreement of their importance. We termed this list the REMROSE‐D (Reporting and Methodological Recommendations for Observational Studies estimating the Effects of Deprescribing medications) guidance.
Results
Twenty‐three candidate recommendations were presented to the Delphi panel. The round 1 survey was completed by 55 participants, and 18 of the 23 candidate recommendations were selected for inclusion. Five candidate recommendations without consensus plus two additional items suggested by participants were included in a round 2 survey of 25 deprescribing researchers. Five of these seven items garnered consensus for inclusion, and two were excluded. The final REMROSE‐D guidance contains 23 recommendations for the methods and reporting of observational research on deprescribing.
Conclusion
To ensure rigor and reproducibility in observational studies of the effects of deprescribing, the REMROSE‐D guidance provides recommendations for important reporting and methods considerations, including time zero, precise definitions of deprescribing, addressing confounding by indication, and careful consideration of follow‐up to avoid immortal time bias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Services, Policy, & Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
- Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
- Division of Geriatric Medicine and Center for Aging and Health, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA.
- Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
ORCID-Profile: Joshua D Niznik, Dimitri Bennett, Denis Talbot, Maurizio Sessa, Caroline Sirois, Andrew R Zullo, Xiaojuan Li, Daniela C Moga
Förderung
- International Society for Pharmacoepidemiology
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Hayes, K. N., Niznik, J. D., Gnjidic, D., Moriarty, F., Bennett, D., Laroche, M. L., Talbot, D., Alcusky, M., Sessa, M., Coe, A. B., Sirois, C., Zullo, A. R., Li, X., Chalasani, S. H., Syed, J., Sawan, M., & Moga, D. C. (2025). The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70255
Vancouver
Hayes KN, Niznik JD, Gnjidic D, Moriarty F, Bennett D, Laroche ML, et al. The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70255
BibTeX
@article{Hayes2025,
author = {Hayes, Kaleen N and Niznik, Joshua D and Gnjidic, Danijela and Moriarty, Frank and Bennett, Dimitri and Laroche, Marie-Laure and Talbot, Denis and Alcusky, Matthew and Sessa, Maurizio and Coe, Antoinette B and Sirois, Caroline and Zullo, Andrew R and Li, Xiaojuan and Chalasani, Sri Harsha and Syed, Jehath and Sawan, Mouna and Moga, Daniela C},
title = {The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70255}
}
EUVIMED